Navigation Links
MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
Date:9/17/2008

DANBURY, Conn., Sept. 17 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it has proposed to the United States Food and Drug Administration to use AFRESA as the trade name for its Technosphere Insulin System.

AFRESA (pronounced uh-FRESS-uh) was unveiled today by Alfred Mann, Chairman and Chief Executive Officer of MannKind, during a ceremony at the company's Danbury, Conn., location that marked the completion and dedication of a new facility for the commercial manufacture of the product.

The events in Danbury included a building dedication, a luncheon, and tours of the 263,900 sq. ft. production facility for invitees, who included investors, medical and industry professionals, scientists, employees, and government officials. The completion of the building phase of this project brings MannKind's investment in plant and equipment at the Danbury site to almost $200 million. The facility is now in the process of being qualified and readied for preapproval inspection by the FDA.

Featuring state-of-the-art equipment and processes and redundant utilities, the new facility includes expansion space that will allow production capacity to be increased to meet expected demand over the next few years. The architect for the project was Kling Stubbins. The engineering firm was Clark Richardson Biskup and the construction manager was Torcon.

MannKind is proud to note that its facility expansion received the 2008 Bronze Vision Award in the Corporate Owner: Industrial/Manufacturing category at the Ninth Annual Constructech Vision Award ceremony, held in Chicago on August 21, 2008. The Constructech Vision Awards honor construction and engineering projects that have solved critical business issues
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. MannKind Corporation Response to Recent Market Events
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014   Veracyte, Inc. ... H. Anderson , president and chief executive officer, will present ... th Annual Healthcare Conference on Tuesday, December 2, 2014 ... . The live audio webcast and subsequent replay ... . Please connect to the website at least 15 minutes ...
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
(Date:11/24/2014)... Massachusetts (PRWEB) November 24, 2014 ... Panels ” from METTLER TOLEDO demonstrates how to ... , Power analytics and sample panel design can ... cycle chemistry and protect against corrosion and deposition. ... up a significant amount of panel space. Additionally, ...
(Date:11/24/2014)... 24, 2014 Senior Vice President, ... dynamic leadership skills, business acumen Elsevier ... information products and services, congratulates Diane Bartoli , ... and Workflow, Elsevier Clinical Solutions, for being recognized in ... Awards issue of Profiles in Diversity Journal ...
Breaking Biology Technology:Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3
... 6 Axelar AB today announced successful,completion of ... phase I/II,clinical trial on cancer patients with its ... inhibitor which has no effects,on the closely related ... on,patients having terminal cancer disease. The results showed ...
... -- Simcere Pharmaceutical Group,(NYSE: SCR ), ... and,innovative anti-cancer pharmaceuticals in China, announced today that ... on Monday, May 18, 2009,after the market closes ... Ren, and chief financial officer, Frank Zhigang Zhao, ...
... 5 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today ... For the first quarter of 2009, the Company reported a ... a net loss of $21.1 million, or $0.55 per share, for ... 2009 were $0.7 million compared with $1.8 million for the same ...
Cached Biology Technology:Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB 2Simcere Pharmaceutical Group to Announce 2009 First Quarter Earnings on Monday, May 18, 2009 2Neurocrine Biosciences Reports First Quarter 2009 Results 2Neurocrine Biosciences Reports First Quarter 2009 Results 3Neurocrine Biosciences Reports First Quarter 2009 Results 4Neurocrine Biosciences Reports First Quarter 2009 Results 5Neurocrine Biosciences Reports First Quarter 2009 Results 6Neurocrine Biosciences Reports First Quarter 2009 Results 7Neurocrine Biosciences Reports First Quarter 2009 Results 8
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
(Date:11/7/2014)... -- Leading Biometric companies aim to provide consumers ... transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ), Microsoft Corporation ... EBAY ) and MasterCard Inc. (NYSE: MA) NXT-ID, ... authentication company focused on the growing mobile commerce is pleased ...
(Date:11/6/2014)... Medicine, Inc, a Baltimore-based bioinformatics company focused on ... a research collaboration with the international leader in ... CSBR). , "There are many companies utilizing advances ... TumorGraft technology is unique in a way that ... vast amounts of valuable data. Our bioinformatic analysis ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... issue of Genes & Development, Dr. Karlene Cimprich and ... structure sufficient to activate the ATR-mediated DNA damage checkpoint. ... says Dr. Cimprich. "The ability to precisely define and ... an experimental system will enable us to control, quantitative ...
... one cause of high blood pressure lies within the brain, ... forward by scientists at the University of Bristol, UK, and ... Hidefumi Waki, working in a research group led by Professor ... JAM-1 (junctional adhesion molecule-1), which is located in the walls ...
... Trek: The Next Generation," Geordi La Forge is a ... special implants in his eyes. While the Star Trek ... the 21st century may not have to wait that ... a University of Missouri-Columbia veterinary ophthalmologist, has been working ...
Cached Biology News:Blame the brain for high blood pressure 2MU researcher placing eye implants in cats to help humans see 2
... and efficient method for purification of DNA fragments ... fragments selectively absorbed in the spin column after ... room temperature for PCR product with equal volume ... DNA can be purified with a single prep ...
BlotGel application pool -see Blotters (Semi-Dry) for more info...
lid holder -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD45RA TAC is designed to deplete human CD45RA from samples to isolate memory CD4+ or CD8+ T cells....
Biology Products: